Document:

Exhibit
10.3

AMENDED AND RESTATED
REIMBURSEMENT AND INDEMNITY AGREEMENT

This Amended and Restated
Reimbursement and Indemnity Agreement (this “Agreement”)
is made as of the 17th day of
January, 2007, by CLARIENT, INC.,
a Delaware corporation (“Clarient”),
in favor of SAFEGUARD DELAWARE, INC.,
a Delaware corporation (“SDI”)
and SAFEGUARD SCIENTIFICS (DELAWARE),
INC., a Delaware corporation (“SSI”)
and together with SDI (“Safeguard”).

BACKGROUND

A.            Pursuant to a Loan Agreement dated as of February 13,
2003, by and between Clarient and Comerica Bank, N.A. (the “Bank”) (as amended from time to time,
including by a Seventh Amendment thereto dated as of even date herewith (“Amendment No.7”), the “Loan Agreement”), the Bank agreed to
provide to Clarient a revolving line of credit in the maximum aggregate
principal amount of $12,000,000 (the “Loan”).

B.            At the request of Clarient, and as required by the Bank,
Safeguard agreed to guaranty all of the payment obligations of Clarient under
the Loan Agreement pursuant to the terms of that certain Unconditional Guaranty
originally dated as of February 13, 2003 (as amended and affirmed from time to
time (the “Original Guaranty”)).  In connection with Amendment No. 7, Safeguard
is contemporaneously herewith entering into a Third Amended and Restated
Guaranty (the “Guaranty”).

C.            In connection with the execution of that certain Fifth
Amendment to the Loan Agreement on or about August 1, 2005, Clarient and
Safeguard entered into a Reimbursement and Indemnity Agreement dated even
therewith (the “Prior Reimbursement and Indemnity Agreement”).

D.            In consideration of Safeguard’s agreements as set forth
above, Clarient has agreed to pay certain fees to Safeguard, to reimburse
Safeguard for any of the obligations required to be paid or satisfied by
Safeguard pursuant to the Guaranty, and to hold Safeguard harmless from and
against any claims made against Safeguard on account of the Guaranty, on the
terms and subject to the conditions set forth below.

E.             All capitalized terms used and not otherwise defined
herein shall have the respective meanings ascribed thereto in the Guaranty.

AGREEMENT

NOW, THEREFORE in
consideration of the foregoing and of the covenants and mutual agreements set
forth below, and intending to be legally bound, the parties agree to amend and
restate the Prior Reimbursement and Indemnity Agreement to be as follows:

1.     Payments,
Performance, Covenants.

(a)   In
the event Comerica makes any demand on Clarient, or Clarient is otherwise
required to perform any obligations under the Loan Agreement (including without
limitation, any payment obligation) or any other Loan Document, Clarient
promptly shall perform its obligations under the Loan Agreement or applicable
Loan Document.

(b)   In
the event any such amount is not timely paid or such obligation is not timely
performed by Clarient and Comerica seeks to enforce Safeguard’s Guaranty,
Clarient shall 

reimburse to Safeguard the aggregate amount of all funds advanced by
Safeguard on account of such obligation, together with interest on such amount
at an annual rate equal to (i) the prime rate (as defined below) plus 4% for
amounts up to $8,500,000, and (ii) the greater of (x) 12% or (y) the prime rate
(as defined below) plus 8% (the “Expansion Rate”)
for amounts in excess of $8,500,000, from the date of payment by Safeguard
until all such amounts have been repaid by Clarient.  For the purpose of this Agreement, “prime
rate” shall mean the variable rate of interest, per annum, most recently
announced by Comerica Bank, as its “prime rate,” whether or not such announced
rate is the lowest rate available from such bank.

(c)   Clarient
will not agree to any amendment, modification, waiver or supplement to the
Comerica Loan Agreement or any of the documents, instruments or agreements
executed in connection therewith (collectively, the “Loan Documents”) without the prior written consent of each
of SDI and SSI.

(d)   For
so long as the Loan Documents permit Clarient to borrow in excess of
$8,500,000:

(i)            Clarient will implement working capital and cash flow
monitoring analytics as directed by Safeguard.

(ii)           Clarient will obtain Safeguard’s prior written approval
prior to (i) borrowing any principal amount in excess of $8,500,000 under the
Loan (which approval shall not be unreasonably withheld prior to the Expansion
End Date (as defined below) for borrowings to be used to fund ordinary course
operating expenses) or (ii) incurring any other indebtedness (other than under
Clarient’s current loan and security agreements with General Electric Capital
Corporation or its affiliates).

(e)   Notwithstanding Section 1(d), after Clarient has reduced its
borrowings under the Loan Documents to a principal amount that is equal to or
less than $8,500,000, Clarient shall not borrow any amount in excess of $8,500,000
without Safeguard’s prior written approval.

2.     Consideration.  As consideration for Safeguard providing the
Guaranty, Clarient agrees to:

(a)   concurrently
with the execution of the Guaranty, pay to Safeguard a commitment fee in the
form of a four-year warrant to purchase 100,000 shares of Clarient common
stock, par value $0.01 per share (“Common Stock”), with an exercise price of
$0.01 per share, pursuant to the form of warrant attached hereto as Exhibit
A.

(b)   pay
Safeguard a usage fee of an amount equal to the sum of:

(i)            1.125% of the daily weighted average of the principal
amounts outstanding under the line of credit during each calendar quarter of
the term of the line of credit,

(ii)           with respect to the daily weighted average of the
principal amounts (if any) in excess of $8,500,000 outstanding under the line
of credit during each calendar quarter of the term of the line of credit (the “Expansion
Balance”), an additional 0.875% of the Expansion Balance, and

(iii)          with respect to any Expansion Balance existing after the
Expansion End Date, (A) 25% of the Expansion Rate less (B) 2%;

 2
 

in each case payable within thirty (30) days after the end of each
calendar quarter with respect to amounts outstanding under the line of credit
during the quarter preceding the payment date. 
Payments for fractional calendar quarters at the beginning and end of
the term of the line of credit will be prorated based on the number of days in
the fractional quarter included in the term of the line of credit divided by
the total number of days in the calendar quarter.  All payments will be made by wire transfer in
immediately available funds to such account as Safeguard shall designate from
time to time.

(c)   concurrently
with the execution of the Guaranty, pay Safeguard a facility maintenance fee in
the form of a four-year warrant to purchase up to 250,000 shares of Common
Stock with an exercise price of $1.64 per share, pursuant to the form of
warrant attached hereto as Exhibit B.

Safeguard
may require additional consideration to be agreed by the parties in the event
that both (a) Clarient’s borrowings under the Loan Agreement exceed $8,500,000
after the date (the “Expansion End Date”) that is the earlier to occur of (i)
April 30, 2007 or (ii) the date Clarient consummates an asset sale or debt
and/or equity financing that results in net proceeds to Clarient in excess of
$7,000,000 in a single or series of related transactions and (b) the Guaranty
is reaffirmed, amended (other than an amendment reducing the maximum amount of
the principal guaranteed thereunder to $8,500,000 or less) or has not expired
or been terminated on or before such date; provided, however, that without
limiting Safeguard’s right to require additional consideration under the
circumstances described above, Safeguard agrees to (x) reaffirm the Guaranty in
a manner and for consideration consistent with past practice in connection with
the extension of the maturity date of the Loan Agreement, and (y) cooperate
with Clarient to obtain such extension on terms and conditions consistent with
past practice.  If, following the
Expansion End Date, Clarient has reduced its borrowings under the Loan
Agreement to $8,500,000 or less, the parties will cooperate with each other to
amend the Guaranty and the Loan Agreement so as to effect the reduction of the
amount of principal guaranteed under the Guaranty to $8,500,000.

3.     Obligations
of Clarient.  The obligations of
Clarient  under this Agreement shall be
absolute, unconditional and irrevocable, shall apply to the fullest extent
authorized or permitted by any applicable law, under and shall be paid and
performed strictly in accordance with the terms of this Agreement, under all
circumstances whatsoever, including, without limitation, the following
circumstances:

(a)   Any
lack of validity or enforceability of this Agreement;

(b)   The
existence of any claim, set-off, defense or other rights which Clarient may
have at any time against Safeguard or any other person or entity, whether or
not in connection with this Agreement; or

(c)   Any
other circumstance or happening whatsoever, whether or not similar to any of
the foregoing.

4.     Representations
and Warranties of Clarient.  Clarient
hereby represents and warrants to Safeguard as follows:

(a)   Organization
and Standing.  Clarient is a corporation,
duly organized, validly existing and in good standing under the laws of the
State of Delaware and has all requisite power and authority to carry on its
business as now being conducted.

(b)   Authority;
Enforceability.  Clarient has all
requisite power and authority to enter into this Agreement and to consummate
the transactions contemplated hereby.

 3
 

(c)   Execution
of Agreement.  This Agreement has
been duly executed and delivered by Clarient. 
The execution, delivery and performance of this Agreement will not cause
any default, breach or violation of any provision of any material agreement to
which Clarient is a party or by which any of Clarient’s assets are bound.

(d)   Validity
of Agreement.  This Agreement
constitutes the legal, valid and binding obligation of Clarient, enforceable in
accordance with its terms.

(e)   Approvals.  No approval, authorization, consent or other
order or action of or filing with any governmental or administrative entity or
any other person is required for the execution and delivery by Clarient of this
Agreement or such other agreements and instruments required hereunder or for
the consummation by Clarient of the transactions contemplated hereby or
thereby.

(f)    Violation
of Laws or Agreements.  The making
and performance of this Agreement and the other documents, agreements and
actions required hereunder or thereunder will not violate any provisions of any
law, federal, state or local rule or regulation, or any judgment, decree, award
or order of any court or other governmental entity, agency or arbitrator to
which Clarient is subject.

5.     Events
of Default.  The occurrence of one or
more of the following events shall constitute an event of default hereunder
(each, an “Event of Default”):

(a)  
If Clarient fails to make any payment due to Safeguard under this Agreement, in
each case within five (5) days after demand therefor from Safeguard that the
same shall be due and payable.

(b)   Clarient
fails to observe or perform any material covenant or agreement required to be
observed or performed by it under this Agreement within five (5) days after
Clarient’s Chief Executive Officer, Chief Financial Officer and/or Controller
knew or should have known of its failure to so observe or perform.

(c)   If
any representation or warranty of Clarient under this Agreement shall be false
or misleading in any material respect when made.

(d)   If
custody or control of any substantial part of the property of Clarient shall be
assumed by any governmental agency or any court of competent jurisdiction at
the instance of any governmental agency; if any material license or franchise
shall be suspended, revoked or otherwise terminated the effect of which would
be to affect materially and adversely the operations of Clarient; or if any
governmental regulatory authority or judicial body shall make any other final
non-appealable determination the effect of which would be to affect materially
and adversely the operations of Clarient.

(e)   If
Clarient:  becomes insolvent, bankrupt or
generally fails to pay its debts as such debts become due; is adjudicated
insolvent or bankrupt; admits in writing its inability to pay its debts; or
shall suffer a custodian, receiver or trustee for it or substantially all of
its property to be appointed and if appointed without its consent, not be
discharged within thirty (30) days; makes an assignment for the benefit of
creditors; or suffers proceedings under any law related to bankruptcy,
insolvency, liquidation or the reorganization, readjustment or the release of
debtors to be instituted against it and if contested by it not dismissed or
stayed within sixty (60) days; if proceedings under any law related to
bankruptcy, insolvency, liquidation, or the reorganization, readjustment or the
release of debtors is instituted or commenced by Clarient; or if any order for
relief is entered relating to any of the foregoing proceedings; if Clarient
shall call a meeting of its creditors with a view to arranging a composition or

 4
 

adjustment of its debts; or if Clarient shall by any act or failure to
act indicate its consent to, approval of or acquiescence in any of the
foregoing.

6.     Remedies
Upon Default.  Upon the occurrence of
any Event of Default, the entire amount of reimbursement due hereunder, plus
any and all interest accrued thereon at the rate set forth in Section 1 hereof,
plus all other sums due and payable to Safeguard hereunder shall, at the option
of Safeguard become due and payable immediately without presentment, demand,
notice of nonpayment, protest, notice of protest, or other notice of dishonor,
all of which are hereby expressly waived by Clarient.

7.     Remedies
Cumulative, etc.

(a)   No
right or remedy conferred upon or reserved to Safeguard hereunder or now or
hereafter existing at law or in equity is intended to be exclusive of any other
right or remedy, and each and every such right or remedy shall be cumulative
and concurrent, and in addition to every other such right or remedy, and may be
pursued singly, concurrently, successively or otherwise, at the sole discretion
of Safeguard and shall not be exhausted by any one exercise thereof but may be
exercised as often as occasion therefor shall occur.

(b)   Clarient
hereby waives presentment, demand, notice of nonpayment, protest, notice of
protest, notice of dishonor and any and all other notices in connection with
any default in the payment of, or any enforcement of the payment of, all
amounts due under this Agreement.  To the
extent permitted by law, Clarient waives the right to any stay of execution and
the benefit of all exemption laws now or hereafter in effect.

(c)   Clarient
agrees that any action or proceeding against it to enforce the Agreement may be
commenced in state or federal court in any county in the Commonwealth of
Pennsylvania in which Safeguard and/or its successors or assigns has an
office.  Clarient waives personal service
of process and agrees that a summons and complaint commencing an action or
proceeding in any such court shall be properly served and shall confer personal
jurisdiction if served by registered or certified mail in accordance with the
notice provisions set forth herein.

(d)   Clarient
acknowledges and agrees that Safeguard shall be subrogated to the rights of
Comerica, including, without limitation, with respect to the security interests
granted to Comerica in connection with the Loan Documents, in the event
Safeguard is required to make any payments on account of the Guaranty.

8.     Termination.  This Agreement shall remain in full force and
effect and shall terminate on the later to occur of (i) the date that the Guaranty
is terminated or expires or (ii) the date that all obligations of Clarient to
Safeguard, and all obligations of Clarient hereunder have been paid in full and
satisfied and; in each case, after the expiration of  the period during which any payment by
Clarient is or may be subject to rescission, avoidance or refund under the
United States Bankruptcy Code (or any similar state statute).

9.     Indemnification.

(a)   Clarient
hereby agrees to indemnify, protect, defend and hold harmless Safeguard and its
officers, directors, employees, successors and assigns, (collectively, the “Indemnified Parties”), from and against any and all claims,
damages, losses, liabilities, costs or expenses of any kind or nature and from
any suits, claims or demands, including reasonable attorney’s fees incurred in
investigating or defending such claim, suffered by any of them and caused by,
relating to, arising out of, 

 5
 

resulting from, or in any way connected with this Agreement or the
transactions contemplated hereby (unless determined by a final judgment of a
court of competent jurisdiction to have been caused solely by the gross
negligence or willful misconduct of the Indemnified Parties) including without
limitation:

(i)            by
reason of any breach of any representation or warranty of Clarient in this
Agreement;

(ii)           by
reason of, in connection with, or as a consequence of any default by Clarient,
in the performance or observance of any term, condition, covenant, or
undertaking contained in this Agreement or any other document to be observed or
performed by Clarient;

(iii)          by
reason of or in connection with any litigation or other proceeding in any way
restraining, enjoining, questioning or affecting performance or obligation
hereunder; and

(iv)          by
reason of or in connection with its obligations under the Loan Documents and
its payment and reimbursement obligations contemplated by Section 1 hereof.

(b)   In
case any action shall be brought against Safeguard or any other Indemnified
Party in respect to which indemnity may be sought against Clarient, Safeguard
or such other Indemnified Party shall promptly notify Clarient and Clarient
shall assume the defense thereof, including the employment of counsel selected
by Clarient  and satisfactory to Safeguard,
the payment of all costs and expenses and the right to negotiate and consent to
settlement.  The failure of Safeguard to
so notify Clarient shall not relieve Clarient of any liability it may have
under the foregoing indemnification provisions or from any liability which it
may otherwise have to Safeguard or any of the other Indemnified Parties except
to the extent Clarient is materially prejudiced thereby.  Safeguard shall have the right, at its sole
option, to employ separate counsel in any such action and to participate in the
defense thereof.  Clarient and
retain  its own counsel, but the fees and
expenses of such counsel shall be at the expense of  Safeguard unless (i) Clarient and
Safeguard  have  agreed 
in writing to the retention of such counsel; or  (ii) the named parties to any such litigation
or proceeding (including  any impleaded
parties) include Clarient and Safeguard and representation of both parties by
the same counsel would, in the opinion 
of  counsel to Safeguard, be
inappropriate due to actual or potential conflicts of interests between
Clarient and Safeguard. Clarient  shall
not be liable for any settlement of any such action effected without its
consent, which consent shall not be unreasonably withheld, delayed or
conditioned, but if settled with Clarient’s consent, or if there shall be a
final judgment for the claimant in any such action, Clarient  agrees to indemnify and hold harmless
Safeguard  from and against any loss or
liability by reason of such settlement or judgment.

(c)   The
provisions of this Section 9 shall survive the repayment or other satisfaction
of the obligations of Clarient hereunder.

10.   Notices.  All notices, requests, demands and other
communications that this Agreement requires or permits shall be in writing and
shall be sent by overnight courier providing delivery receipt, or by certified
mail, return receipt requested, or by telecopy or hand delivery to the
following addresses:

	
  

  	
  If to Clarient:

  	
  Clarient, Inc.

  
	
   

  	
  31 Columbia 

  Aliso Viejo, CA 92656 

  Attention: James Agnello, Chief Financial Officer 

  Telephone: (949) 425-5881

  

 

 6
 

 

	
  

  	
  Fax:(949) 425-5865

  
	
   

  	
   

  
	
   

  	
  If to Safeguard:

  	
  c/o Safeguard Scientifics, Inc.

  
	
   

  	
  435 Devon Park Drive 

  800 The Safeguard Building 

  Wayne, PA 19087 

  Attention: Steven J. Feder, Senior Vice President and General Counsel 

  Telephone: (610) 975 - 4984 

  Fax:(610) 482 - 9105

  
			

All notices, requests,
demands and other communications provided in accordance with the provisions of
this Agreement shall be effective:  (i)
if sent by overnight courier or telecopier, when received, (ii) if sent by
certified mail, return receipt requested, the third day after sending, and
(iii) if given by hand delivery, when delivered.

11.   Amendments.  The provisions of this Agreement may be
amended only by a written agreement signed by Clarient.

12.   Governing
Law and Jurisdiction.  This Agreement
shall be governed by, construed and enforced in accordance with the laws of the
Commonwealth of Pennsylvania, without regard to the conflicts of laws
provisions.

13.   Continuing
Obligation.  This Agreement is a
continuing obligation and shall (a) be binding upon Clarient and its respective
its successors and assigns, and (b) inure to the benefit of and be enforceable
by Safeguard against Clarient (and its successors, transferees and assigns); provided,
that Clarient may not assign all or any part of their obligations hereunder
without the prior written consent of Safeguard, which consent shall not be
unreasonably withheld.

14.   Savings
Clause.  Whenever possible, each
provision of this Agreement shall be interpreted in a manner as to be effective
and valid under applicable law, but if any provision of this Agreement shall be
prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of
this Agreement.

15.   Severability.  In case any one or more of the provisions
contained in this Agreement shall, for any reason, be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect the validity of any other provision of this
Agreement, and such provision(s) shall be deemed modified to the extent
necessary to make it enforceable.

16.   Jury
Trial Waiver. EACH PARTY HERETO HEREBY KNOWINGLY, VOLUNTARILY, AND
INTENTIONALLY WAIVES ANY RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF
ANY LITIGATION BASED HEREON OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS
AGREEMENT OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL
OR WRITTEN) OR ACTIONS OF ANY OTHER PARTY. 
THIS PROVISION IS A MATERIAL INDUCEMENT FOR SAFEGUARD’S ENTERING INTO
THIS AGREEMENT.

EACH PARTY ACKNOWLEDGES THAT
IT HAS HAD THE ASSISTANCE OF COUNSEL IN THE REVIEW AND EXECUTION OF THIS
AGREEMENT AND FURTHER ACKNOWLEDGES THAT THE MEANING AND EFFECT OF THE FOREGOING
WAIVER OF JURY TRIAL HAS BEEN FULLY EXPLAINED BY SUCH COUNSEL.

 7
 

17.   Survival of Representations and Warranties.  All representations and warranties contained
or incorporated herein or made in writing in connection herewith shall survive
the execution and delivery of this Agreement.

18.   Counterparts.  This
Agreement may be executed in more than one counterpart, including by facsimile
signature, all of which, together, constitute one and the same instrument.

19.   No Third-Party Beneficiaries.  This Agreement is intended for the benefit of
the parties hereto; there are no third-party beneficiaries of this Agreement.

20.   Entire Agreement. 
This Agreement embodies and reflects the entire agreement between the
parties with respect to the matters set forth herein, and there are no other
agreements, understandings, representations or warranties between the parties
other than those set forth in this Agreement.

 8
 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement on the date first
set forth above.

	
   

  	
  CLARIENT, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ James V.
  Agnello

  	
   

  
	
   

  	
   

  	
  Name: James V.
  Agnello

  
	
   

  	
   

  	
  Title: Senior
  Vice President and CFO

  
	
   

  	
   

  
	
   

  	
  SAFEGUARD
  DELAWARE, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Steven J. Feder

  	
   

  
	
   

  	
   

  	
  Name: Steven J.
  Feder

  
	
   

  	
   

  	
  Title: Vice
  President

  
	
   

  	
   

  
	
   

  	
  SAFEGUARD
  SCIENTIFICS (DELAWARE), INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Steven J.
  Feder

  	
   

  
	
   

  	
   

  	
  Name: Steven J.
  Feder

  
	
   

  	
   

  	
  Title: Vice
  President

  
	
   

  	
   

  
							

 

 9

EXHIBIT A

 A-1
 

EXHIBIT B

 A-2Exhibit 10.4

WAIVER AND EIGHTH AMENDMENT 

TO

LOAN AGREEMENT

This Waiver and Eighth Amendment to Loan Agreement is
entered into as of February 28, 2007 (the “Amendment”) by and between COMERICA
BANK (“Bank”) and CLARIENT, INC. (“Borrower”).

RECITALS

Borrower and Bank are parties to that certain Loan
Agreement dated as of February 13, 2003, as amended, including, without
limitation, by that certain First Amendment to Loan Agreement dated as of October
21, 2003, that certain Second Amendment to Loan Agreement dated as of January
22, 2004, that certain Third Amendment to Loan Agreement dated as of January
31, 2005, that certain Fourth Amendment to Loan Agreement dated as of March 11,
2005, that certain Consent and Waiver dated as of July 13, 2005, that certain letter
agreement dated as of January 26, 2006, that certain Waiver and Fifth Amendment
to Loan Agreement dated as of August 1, 2006, that certain Sixth Amendment to
Loan Agreement dated as of February 28, 2006, and that certain Seventh
Amendment to Loan Agreement dated as of January 17, 2007 (collectively, the “Agreement”).  The parties desire to further amend the
Agreement in accordance with the terms of this Amendment.

NOW, THEREFORE, the parties agree as follows:

1.             The following defined term is amended in Section 1.1 of
the Agreement to read as follows;

“Revolving Maturity Date”
means February 27, 2008.

2.             Bank hereby waives Borrower’s failure to comply with
Section 6.8 (Tangible Net Worth covenant) of the Agreement for the month ended
February 28, 2007.  Bank does not waive
Borrower’s obligations under such Section for any period after February 28,
2007, and Bank does not waive any other failure by Borrower to perform its
Obligations under the Loan Documents. 
This waiver is not a continuing waiver with respect to any failure to
perform any Obligation after February 28, 2007.

3.             Unless otherwise defined, all initially capitalized
terms in this Amendment shall have the respective meanings set forth in the
Agreement.  The Agreement, as amended
hereby, shall be and remain in full force and effect in accordance with its
terms and hereby is ratified and confirmed in all respects.  Except as expressly set forth herein, the
execution, delivery, and performance of this Amendment shall not operate as a
waiver of, or as an amendment of, any right, power, or remedy of Bank under the
Agreement, as in effect prior to the date hereof.  Borrower ratifies and reaffirms the
continuing effectiveness of all promissory notes, guaranties, security
agreements, mortgages, deeds of trust, environmental agreements, and all other
instruments, documents and agreements entered into in connection with the
Agreement.

4.             This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one instrument.

5.             As a condition to the effectiveness of this Amendment,
Bank shall have received, in form and substance satisfactory to Bank, the
following:

(a)           this Amendment, duly
executed by Borrower;

(b)           an officer’s certificate
of Borrower with respect to incumbency and resolutions authorizing the
execution and delivery of this Amendment;

(c)           an Affirmation of
Guaranty, duly executed by Safeguard Delaware, Inc. and Safeguard Scientifics
(Delaware), Inc.;

(d)           a nonrefundable renewal
fee on account of the Revolving Line equal to $12,000 plus an amount equal to
all Bank Expenses incurred through the date of this Amendment; and

 1
 

(e)           such other
documents, and completion of such other matters, as Bank may reasonably deem
necessary or appropriate.

IN WITNESS WHEREOF, the undersigned have executed this
Amendment as of the first date above written.

	
  

  	
  CLARIENT, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ James V. Agnello

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  Title: 

  	
  Senior Vice President and CFO

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  COMERICA BANK

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ Beth Kinsey

  	
   

  
	
   

  	
   

  
	
   

  	
  Title: 

  	
  Senior Vice President

  	
   

  
								

 

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]